Latest News & Events
Hemanext Inc. Announces a Significant Milestone with FDA Marketing Authorization for Hemanext ONE®, Hemanext’s Innovative Red Blood Cell (RBC) Processing and Storage System
Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo...
Hemanext Announces Founder Martin Cannon’s Retirement, Appoints Andrew Dunham as CEO, and Raises Funding for Growth
LEXINGTON, Mass., September 18, 2023, – Hemanext Inc., a leading innovator in blood processing,...
Hemanext Announces Membership in European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
LEXINGTON, Mass., July 5, 2023, – Hemanext Inc., a leading innovator in blood processing, storage,...
Hemanext Announces a Strategic Partnership and Investment from Vitalant
Partnership to include research and development at Vitalant Innovation Center LEXINGTON, Mass.,...
INVESTORS
Current and prospective investors access to the investor Portal
COVID 19 Updates
Follow the course of COVID-19 and locate where to donate blood
Educational Symposiums
View educational material and interesting presentations
Our Science
Learn about the journey of red blood cells after donation including degradation that occurs during storage and discover the potential of hypoxic storage to alleviate this problem.
Stored Blood
The average human body stores about 5.6 liters of blood. As it circulates through the body several times each minute, it accomplishes a variety of functions.
Storage Lesion
The existence of the storage lesion process has been well established, and recent scientific work has increased the precision and depth.
Clinical Implications
Numerous studies pertaining to clinical implications of storage lesion suggest a linkage to hyper-coagulability, inflammation, impaired perfusion, immuno-modulation, organ dysfunction13, and mortality14.
Hypoxic Storage
Hemanext Research
Learn more about Hemanext and take a closer look at our publications, studies, and posters focused on blood quality and red blood cell characterization.